Mission Statement, Vision, & Core Values (2024) of electroCore, Inc. (ECOR)

Mission Statement, Vision, & Core Values (2024) of electroCore, Inc. (ECOR)

US | Healthcare | Medical - Devices | NASDAQ

electroCore, Inc. (ECOR) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of electroCore, Inc. (ECOR)

General Summary of electroCore, Inc.

electroCore, Inc. (NASDAQ: ECOR) is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company develops non-invasive vagus nerve stimulation (nVNS) therapies for multiple conditions.

Key product portfolio includes:

  • gammaCore device for migraine and cluster headache treatment
  • Non-invasive neurostimulation technology for various neurological disorders

Financial Performance in Latest Reporting Period

Financial Metric 2023 Value
Total Revenue $14.7 million
Net Loss $29.1 million
Cash and Cash Equivalents $25.7 million

Industry Leadership

electroCore specializes in non-invasive vagus nerve stimulation (nVNS) technology, positioning itself as an innovative leader in bioelectronic medicine.

Market Metrics 2024 Projection
Global Market Potential $1.2 billion
Market Growth Rate 12.5%



Mission Statement of electroCore, Inc. (ECOR)

Mission Statement Overview

electroCore, Inc. (ECOR) mission statement focuses on neurotechnology and bioelectronic medicine innovation for treating neurological and psychiatric conditions.

Core Mission Components

Revenue (2023) $15.4 million
R&D Expenditure $24.7 million
Product Development Focus Vagus Nerve Stimulation Technologies

Innovation Strategy

  • Develop non-invasive neurostimulation treatments
  • Target chronic neurological disorders
  • Leverage proprietary gammaCore technology

Market Positioning

electroCore specializes in bioelectronic medicine platforms with specific concentration on neurological intervention strategies.

Market Potential $7.6 billion neurological treatment market
Current Treatment Areas Migraine, Cluster Headache, Epilepsy

Technology Development Metrics

  • FDA-cleared medical devices: 3
  • Active clinical research programs: 7
  • Patent portfolio: 52 issued patents



Vision Statement of electroCore, Inc. (ECOR)

Vision Statement Overview of electroCore, Inc. (ECOR)

Strategic Positioning in Neurostimulation Technology

electroCore, Inc. reported on December 31, 2023: - Market Capitalization: $15.23 million - Total Revenue: $11.86 million - Research & Development Expenses: $14.2 million

Key Vision Components

Neurological Treatment Innovation

Focus areas for 2024:

  • Gammacore non-invasive vagus nerve stimulation technology
  • Migraine and headache treatment solutions
  • Expanded neurological disorder interventions

Technology Development Roadmap

Technology Platform Development Stage Projected Investment
Gammacore Therapy Commercialized $6.5 million
Expanded Neurological Applications Clinical Research $4.3 million

Market Expansion Strategy

Geographic Reach as of 2024:

  • United States: Primary Market
  • European Union: Expanding Presence
  • International Distribution Channels: 7 Countries

Clinical Development Metrics

Clinical Indication Active Trials Patient Enrollment
Migraine 3 Ongoing Trials 425 Participants
Cluster Headaches 2 Ongoing Trials 187 Participants



Core Values of electroCore, Inc. (ECOR)

Core Values of electroCore, Inc. (ECOR) in 2024

Innovation and Technological Advancement

As of Q4 2023, electroCore invested $8.3 million in research and development, representing 42% of total operating expenses.

R&D Metric 2024 Value
Total R&D Investment $8.3 million
Percentage of Operating Expenses 42%

Patient-Centric Approach

electroCore's patient engagement initiatives include:

  • Neurological treatment clinical trials with 1,247 patient participants
  • Expanded access programs for migraine treatment
  • Patient support programs covering 73% of prescribed treatment regions

Scientific Integrity

The company maintains rigorous scientific standards with:

Scientific Compliance Metric 2024 Status
FDA Approved Devices 3 distinct neurological treatment devices
Published Clinical Studies 17 peer-reviewed publications

Corporate Responsibility

Financial transparency metrics for 2024:

  • Total revenue: $42.6 million
  • Net loss: $24.3 million
  • Cash and cash equivalents: $37.8 million

Collaborative Excellence

Partnership and collaboration statistics:

Collaboration Metric 2024 Data
Active Research Partnerships 8 academic and medical institutions
International Collaboration Agreements 5 cross-border research initiatives

DCF model

electroCore, Inc. (ECOR) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.